At ESMO 2026, clinicians and researchers continued dissecting the impact of Merck and Moderna’s personalized cancer vaccine Phase 3 data as the meeting moved from headline results into next-step questions for development. The program coverage highlighted the strength of clinician interest in the personalized mRNA approach and framed upcoming efforts as part of a broader shift toward understanding which patients benefit most and how to operationalize individualized vaccine manufacturing. The editorial-style reporting emphasizes momentum rather than clinical details, but it underscores that the field’s focus is shifting from “can it work” to how the platform should evolve after a pivotal clinical signal.